13 December 2016
Amersham, UK / Malvern, PA – December 13, 2016 – Phlexglobal, the world-renowned thought leaders and specialists in the provision of electronic Trial Master File (eTMF) systems and services to the life sciences industry, today announced a significant investment by funds managed by Vitruvian Partners (“Vitruvian”). The transaction establishes Vitruvian as majority shareholder of Phlexglobal, while previous majority investor Bridgepoint Development Capital (“BDC”) will exit the company.
To access investor reports through the web based reporting facility, please fill in the form to register for an account.
The information submitted on this form will be used for the sole purpose of registering you as an account user and will not be shared with third parties.